HALO – Halozyme Therapeutics, Inc.
Float Short %
11.59
Margin Of Safety %
26
Put/Call OI Ratio
0.36
EPS Next Q Diff
EPS Last/This Y
EPS This/Next Y
1.83
Price
70.96
Target Price
84.5
Analyst Recom
2.11
Performance Q
1.26
Upside
22.8%
Beta
0.98
Ticker: HALO
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-01-23 | HALO | 69.19 | 0.46 | 0.98 | 11650 |
| 2026-01-26 | HALO | 69.89 | 0.47 | 0.21 | 11828 |
| 2026-01-27 | HALO | 70.21 | 0.47 | 0.44 | 12007 |
| 2026-01-28 | HALO | 72.84 | 0.48 | 0.14 | 12275 |
| 2026-01-29 | HALO | 73.32 | 0.47 | 0.10 | 12496 |
| 2026-01-30 | HALO | 71.63 | 0.46 | 0.22 | 12695 |
| 2026-02-02 | HALO | 74.44 | 0.46 | 0.22 | 12772 |
| 2026-02-03 | HALO | 76.49 | 0.45 | 0.07 | 12873 |
| 2026-02-05 | HALO | 78.42 | 0.44 | 0.03 | 13159 |
| 2026-02-09 | HALO | 80.5 | 0.34 | 0.27 | 12490 |
| 2026-02-10 | HALO | 80.23 | 0.35 | 0.28 | 12987 |
| 2026-02-11 | HALO | 79.51 | 0.35 | 0.16 | 12993 |
| 2026-02-12 | HALO | 76.94 | 0.35 | 0.62 | 13044 |
| 2026-02-13 | HALO | 79.45 | 0.36 | 0.11 | 13230 |
| 2026-02-17 | HALO | 80.57 | 0.36 | 0.38 | 13262 |
| 2026-02-18 | HALO | 73.33 | 0.35 | 0.40 | 13730 |
| 2026-02-19 | HALO | 72.04 | 0.38 | 0.21 | 14771 |
| 2026-02-20 | HALO | 70.98 | 0.36 | 4.82 | 14966 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-01-23 | HALO | 69.18 | 51.4 | - | 6.25 |
| 2026-01-26 | HALO | 69.86 | 51.4 | - | 6.25 |
| 2026-01-27 | HALO | 70.18 | 51.4 | - | 6.25 |
| 2026-01-28 | HALO | 72.87 | 51.4 | - | 6.25 |
| 2026-01-29 | HALO | 73.33 | 51.4 | - | 6.25 |
| 2026-01-30 | HALO | 71.66 | 51.4 | - | 6.25 |
| 2026-02-02 | HALO | 74.45 | 51.4 | - | 6.25 |
| 2026-02-03 | HALO | 76.60 | 69.7 | - | 6.25 |
| 2026-02-04 | HALO | 77.92 | 69.7 | - | 6.25 |
| 2026-02-05 | HALO | 78.42 | 74.4 | - | 6.25 |
| 2026-02-06 | HALO | 81.21 | 74.4 | - | 6.25 |
| 2026-02-09 | HALO | 80.48 | 74.4 | - | 6.25 |
| 2026-02-10 | HALO | 80.24 | 74.4 | - | 6.25 |
| 2026-02-11 | HALO | 79.51 | 74.4 | - | 6.25 |
| 2026-02-12 | HALO | 76.92 | 74.4 | - | 6.25 |
| 2026-02-13 | HALO | 79.46 | 74.4 | - | 6.25 |
| 2026-02-17 | HALO | 80.54 | 74.4 | - | 6.25 |
| 2026-02-18 | HALO | 73.21 | 74.4 | - | 6.25 |
| 2026-02-19 | HALO | 72.05 | 74.4 | - | 6.25 |
| 2026-02-20 | HALO | 70.96 | 36.8 | - | 8.02 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-01-23 | HALO | -18.11 | 4.59 | 11.87 |
| 2026-01-26 | HALO | -18.11 | 4.61 | 11.87 |
| 2026-01-27 | HALO | -18.11 | 4.61 | 11.87 |
| 2026-01-28 | HALO | -18.11 | 4.61 | 11.69 |
| 2026-01-29 | HALO | -18.11 | 4.61 | 11.69 |
| 2026-01-30 | HALO | -18.11 | 4.61 | 11.69 |
| 2026-02-02 | HALO | -18.11 | 4.23 | 11.69 |
| 2026-02-03 | HALO | -18.11 | 4.23 | 11.69 |
| 2026-02-04 | HALO | -18.11 | 4.23 | 11.69 |
| 2026-02-05 | HALO | -18.11 | 4.23 | 11.69 |
| 2026-02-06 | HALO | -20.56 | 4.23 | 11.69 |
| 2026-02-09 | HALO | -20.56 | 2.12 | 11.69 |
| 2026-02-10 | HALO | -20.56 | 2.12 | 11.73 |
| 2026-02-11 | HALO | -16.78 | 2.12 | 11.66 |
| 2026-02-12 | HALO | -16.78 | 2.12 | 11.63 |
| 2026-02-13 | HALO | -20.56 | 2.12 | 11.63 |
| 2026-02-17 | HALO | -17.60 | 4.40 | 11.63 |
| 2026-02-18 | HALO | -17.48 | 4.40 | 11.63 |
| 2026-02-19 | HALO | -17.48 | 4.40 | 11.63 |
| 2026-02-20 | HALO | -17.42 | 4.40 | 11.59 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
1.52
Avg. EPS Est. Next Quarter
1.8
Insider Transactions
-17.42
Institutional Transactions
4.4
Beta
0.98
Average Sales Estimate Current Quarter
358
Average Sales Estimate Next Quarter
401
Fair Value
89.73
Quality Score
97
Growth Score
100
Sentiment Score
13
Actual DrawDown %
13.7
Max Drawdown 5-Year %
-49.1
Target Price
84.5
P/E
28.49
Forward P/E
7.21
PEG
0.2
P/S
6
P/B
171.27
P/Free Cash Flow
13
EPS
2.49
Average EPS Est. Cur. Y
8.02
EPS Next Y. (Est.)
9.85
Target Price Estimates Raised
2
Target Price Estimates Lowered
Profit Margin
22.69
Relative Volume
1.04
Return on Equity vs Sector %
89.2
Return on Equity vs Industry %
106.6
EPS 1 7Days Diff
-0.2
EPS 1 30Days Diff
-0.19
EBIT Estimation
Halozyme Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 423
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California.
stock quote shares HALO – Halozyme Therapeutics, Inc. Stock Price stock today
news today HALO – Halozyme Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch HALO – Halozyme Therapeutics, Inc. yahoo finance google finance
stock history HALO – Halozyme Therapeutics, Inc. invest stock market
stock prices HALO premarket after hours
ticker HALO fair value insiders trading